Alembic Pharmaceuticals receives USFDA final approval for Oseltamivir Phosphate oral suspension (6 mg/mL)

What Alembic announced

On 26 June 2026, Alembic Pharmaceuticals Limited disclosed that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) covering Oseltamivir Phosphate oral suspension, 6 mg/mL. The approval was communicated to both the BSE and NSE listing platforms through a Regulation 30 filing and is accompanied by a formal press release.

"Alembic Pharmaceuticals Limited announces USFDA Final Approval for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL."

The announcement marks the addition of a new influenza‑treatment product to Alembic’s growing generic portfolio in the United States.

Details of the USFDA approval

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD) Tamiflu oral suspension, 6 mg/mL, marketed by Hoffmann‑La Roche, Inc. Oseltamivir Phosphate is an influenza neuraminidase inhibitor (NAI) with two approved indications:

1. Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours.
2. Prophylaxis of influenza A and B in patients 1 year and older.

The approval follows the submission of a complete ANDA dossier that satisfied USFDA’s requirements for safety, efficacy, bioequivalence, and manufacturing quality. No further clinical trials are required for the generic product to be marketed in the United States.

Market potential

According to IQVIA, the estimated market size for Oseltamivir Phosphate oral suspension (6 mg/mL) is US$27 million for the twelve‑month period ending March 2026. This figure reflects the demand for generic influenza treatment and prophylaxis in the United States, a market traditionally dominated by the branded product Tamiflu.

Alembic’s entry into this space could capture a share of the seasonal influenza market, especially given the company’s established manufacturing capabilities and cost‑competitive pricing strategy.

Alembic’s ANDA track record

The approval adds to Alembic’s cumulative 243 ANDA approvals from the USFDA, comprising 223 final approvals and 20 tentative approvals. This milestone underscores the company’s long‑standing focus on regulatory compliance and its ability to navigate the stringent US generic drug approval pathway.

Alembic’s vertically integrated R&D and manufacturing model, supported by state‑of‑the‑art facilities approved by multiple global regulators, has enabled it to build a robust pipeline of generic products across therapeutic classes.

Key facts at a glance

Why this matters for investors

The filing does not involve any equity dilution, share buy‑back, or capital raise; it is purely a regulatory update. However, the approval expands Alembic’s product footprint in the United States, a market that contributes a significant portion of revenue for many Indian generic manufacturers. The addition of a high‑visibility influenza product may enhance the company’s order‑book visibility, especially during the seasonal flu period.

From a compliance perspective, the approval reinforces Alembic’s reputation with the USFDA, potentially smoothing the path for future ANDA submissions. The disclosed market size of US$27 million provides a quantitative gauge of the revenue ceiling for this single product, though actual sales will depend on pricing, market share capture, and seasonal demand.

Investors should note that the announcement is a regulatory milestone rather than a financial transaction. No immediate impact on the balance sheet is expected, but the product could contribute to top‑line growth in upcoming quarters if commercial launch proceeds as planned.

Conclusion

Alembic Pharmaceuticals has secured USFDA final approval for its generic Oseltamivir Phosphate oral suspension (6 mg/mL), a product equivalent to Roche’s Tamiflu. The approval adds to a portfolio of 243 USFDA ANDA clearances and opens a US$27 million market opportunity for the 2025‑26 fiscal year. While the filing does not trigger any immediate financial changes, it strengthens Alembic’s regulatory standing and expands its presence in the lucrative US generic influenza segment. Further commercial details, such as launch timelines and pricing, were not disclosed in the filing.